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Schizophrenia is a complex disorder with many comorbid conditions. In this study, we used polygenic risk scores (PRSs) from
schizophrenia and comorbid traits to explore consistent cluster structure in schizophrenia patients. With 10 comorbid traits, we
found a stable 4-cluster structure in two datasets (MGS and SSCCS). When the same traits and parameters were applied for the
patients in a clinical trial of antipsychotics, the CATIE study, a 5-cluster structure was observed. One of the 4 clusters found in
the MGS and SSCCS was further split into two clusters in CATIE, while the other 3 clusters remained unchanged. For the 5
CATIE clusters, we evaluated their association with the changes of clinical symptoms, neurocognitive functions, and laboratory
tests between the enrollment baseline and the end of Phase I trial. Class I was found responsive to treatment, with significant
reduction for the total, positive, and negative symptoms (p = 0:0001, 0.0099, and 0.0028, respectively), and improvement for
cognitive functions (VIGILANCE, p = 0:0099; PROCESSING SPEED, p = 0:0006; WORKING MEMORY, p = 0:0023; and
REASONING, p = 0:0015). Class II had modest reduction of positive symptoms (p = 0:0492) and better PROCESSING SPEED
(p = 0:0071). Class IV had a specific reduction of negative symptoms (p = 0:0111) and modest cognitive improvement for all
tested domains. Interestingly, Class IV was also associated with decreased lymphocyte counts and increased neutrophil counts,
an indication of ongoing inflammation or immune dysfunction. In contrast, Classes III and V showed no symptom reduction
but a higher level of phosphorus. Overall, our results suggest that PRSs from schizophrenia and comorbid traits can be utilized
to classify patients into subtypes with distinctive clinical features. This genetic susceptibility based subtyping may be useful to
facilitate more effective treatment and outcome prediction.
1. Introduction
Schizophrenia is a severe mental disorder with heteroge-
neous genetic architecture and clinical presentation [1–4].
As a heritable disorder, schizophrenia has an estimated
heritability of about 80% [5], and genome-wide association
studies (GWASs) have identified more than 100 loci [6–9].
Clinically, schizophrenia patients present positive and nega-
tive symptoms and cognitive deficits [3, 4, 10–12]. Further-
more, symptoms presented in individuals may change as
the disease progresses [2]. All these impose great challenges
for both genetic and clinical studies, hindering effective treat-
ment and therapy of this disorder.
Subtyping is an effective approach to reduce heterogene-
ity, and it has been applied to complex diseases such as breast
cancer [13, 14] and stroke [15, 16]. However, subtyping
psychiatric disorders are challenging. Specific to schizophre-
nia, attempts to subtype with clinical symptoms [4, 17–20],
neurocognitive functions [12, 21–26], age of onset [27, 28],
treatment responses [29–31], and specific genetic risk factors
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[24, 32–35], had been reported in the literature. A 5-subtype
classification based on clinical symptoms was enacted in the
Diagnostic and Statistical Manual of Mental Disorders, 4th
Edition (DSM IV) [19]. However, most of these subtyping
systems lack biological underpinning, measurement objectiv-
ity, or systematic perspectives. As a result, they have not been
broadly implemented in clinical practice and have not
demonstrated utility in the patient care. For these reasons,
the 5-subtype classification was removed from DSM V.
Given the challenges and potential benefits, it is important
to consider whether we can develop a data-driven method
to subtype schizophrenia so that the resulting subtypes can
be used to guide clinical practice and have a more homoge-
neous biological mechanism.
Recent findings from large scale GWASs [36] indicated
that pleiotropy is pervasive [37, 38] and that comorbid traits
share some genetic liability [37, 39]. These findings present
us with such an opportunity. We reasoned that schizophre-
nia is comorbid with many other mental disorders [40, 41]
and physical diseases [42] and that many comorbid condi-
tions share genetic liability, genetic factors identified for both
schizophrenia and the diseases and traits comorbid with
schizophrenia may be used as effective classifiers to subtype
schizophrenia. Since these diseases and traits share only par-
tial genetic liability with schizophrenia, i.e., some schizophre-
nia patients share genetic liability with one condition, while
others share liability with a different condition, collectively,
these conditions could segregate schizophrenia patients into
different classes or subtypes. Furthermore, this differential
sharing of genetic liability implies that the resulting subtypes
have distinctive underlying biology, and therefore, more
targeted and subtype-specific treatments may be imposed
for better outcomes. In this study, we hypothesize that the
partial sharing of genetic liability can be used to classify
schizophrenia into distinct subtypes with different dimen-
sions of genetic risk, and the resulting subtypes may reveal
different pathophysiology. An expected outcome of this
hypothesis is that these genetically informed subtypes have
a unique underlying genetic architecture and underpinning
biology that can be verified objectively and accurately by
clinical and laboratory tests.
In this report, we describe our study to test the hypothe-
sis. We started with the selection of traits that are genetically
related to schizophrenia and estimated their polygenic risk
scores (PRSs) in three independent datasets: the Molecular
Genetics of Schizophrenia (MGS), the Swedish Schizophre-
nia Case-Control Study (SSCCS), and the Clinical Antipsy-
chotic Trials for Intervention Effectiveness (CATIE)
datasets. Next, we used hierarchical cluster algorithms to
group subjects by their shared genetic liability in the MGS
dataset. Then, we verified the cluster structure with the
SSCCS and the CATIE datasets. Finally, we validated the
resulting subtypes with clinical, neurocognitive, and labora-
tory tests in the CATIE dataset. The overall study design is
shown in Figure 1. Our results suggest that it is possible to
classify schizophrenia patients based on the partially shared
genetic liability with other comorbid conditions, highlighting
the potential in the genetically based treatment and interven-
tion for schizophrenia.
2. Results
2.1. Selection for Traits Genetically Related to Schizophrenia.
We started our study with PubMed search using keywords
“schizophrenia”, “comorbidity”, and “genome-wide associa-
tion study”, or “GWAS” and cross-linked the traits with data
at GWAS catalog repository website (https://www.ebi.ac.uk/
gwas/) and other sources. As a result, we obtained GWAS
summary statistics for 25 diseases and traits (Table S1).
Using the markers with p ≤ 0:05 in both schizophrenia and
the candidate traits, PRSs from these traits were calculated
for the subjects in MGS [43], SSCCS [7], and CATIE [44,
45] datasets for this study. We conducted linear regression
to evaluate the genetic relationships between schizophrenia
diagnosis and the PRSs calculated from these candidate
traits. Only those traits showing suggestive association signals
(p ≤ 0:15) and the same direction of effect in both MGS and
SSCCS datasets were selected for inclusion in our subtype
classification analyses. As shown in Table 1, 10 traits showed
a consistent correlation with schizophrenia. As expected,
bipolar disorder (BIP) [44], cannabis dependence (cannabis)
[45], and ever smoker vs never smoker (evrSmk) [46] showed
a positive correlation with schizophrenia, whereas subjective
wellbeing (SWB) [47] and verbal and numeric reasoning
(VNR) [48] were negatively correlated with schizophrenia.
Surprisingly, working memory (MEM) [48], Neoopenness
(OPEN) [49], and years of school attended (YoS) [50] were
also positively correlated with schizophrenia.
2.2. Cluster Analyses. Based on the analyses of genetic
relationships, the PRSs of the 10 selected traits along with
those of schizophrenia were used in our cluster analyses.
Our objective here was to find a stable and consistent cluster
structure as the base for our subtyping analyses. Towards this
goal, we first used the R package “NbClust” [51] to explore
the appropriate number of clusters for the MGS dataset and
then validated the structure in the SSCCS dataset. We found
that the 4-cluster solution was the one with the most
endorsements (11 out of 20 indices) for cluster assessment
(Figure 2(a)) for the MGS dataset. When we used the same
parameters to verify the cluster structure with the indepen-
dent SSCCS dataset, we found that the 4-cluster solution also
had the most endorsements (7 out of 20) (Figure 2(b)). Based
on these analyses, we concluded that the 4-cluster solution
was a stable and consistent cluster structure for schizophre-
nia patients when assessed with PRSs from the 10 selected
candidate traits.
With the same parameters from the analyses of both the
MGS and SSCCS datasets, we ran the analyses for another
independent CATIE dataset A 3-cluster solution had the
most endorsements (6 out of 20). However, further examina-
tion of the dendrograms indicated that cluster 1 could be
divided further into three groups for CATIE dataset (the
red, blue, and green clusters in Figure 2(c)). Therefore, we
decided to use a 5-cluster solution for the CATIE dataset.
Of note, if Classes I and IV in the CATIE were merged, it
would result in a 4-cluster structure similar to that observed
from the MGS and SSCCS datasets.
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As mentioned earlier, the central goal of this study was to
evaluate whether schizophrenia had a stable and consistent
subtype structure with genetic and biological underpinning.
The PRSs-based cluster analyses seemed supporting this
notion. In the sections below, we intended to test this
hypothesis by examining class membership association with
a variety of clinical, neurological, and laboratory tests.
2.3. Subtype Class Association with Clinical Symptoms and
Treatment Outcomes. To examine whether the classes had
any pattern in clinical symptoms, we analyzed the association
of class membership with clinical symptoms using the
CATIE study, a multivisit clinical trial of antipsychotics
treatment on schizophrenia that last up to 18 months in the
end Phase I trial [52, 53]. During the trial, clinical evalua-
tions, psychological and behavioral assessments, and labora-
tory tests were performed to evaluate their responses of
antipsychotics the entrance (baseline assessments), each
follow-up visit, and the end of the trial. To evaluate class
membership association with clinical symptoms, we used
the clinical data at baseline and at the end of the 18-month
Phase I trial. We first analyzed the total, positive, and
negative symptoms at the baseline across the classes, and
found that Class II had lower total symptoms and negative
symptoms at baseline as compared to Class I, which was used
as reference (Figure 3).
Next, we examined if any classes were associated with
treatment outcomes as defined by the differences of symptom
counts between baseline and at the end of the 18-month
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Figure 1: A flowchart illustrating the design of the study. The MGS and SSCCS datasets were used to screen for comorbid traits and establish
stable cluster structure. The CATIE dataset was used to verify the derived clusters or classes that were further tested for their association with
clinical symptoms, neurocognitive functions, and laboratory tests.
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total, positive, and negative symptoms were all significantly
reduced (Table 2). The total symptom counts reduced by
4.17 (95% CI 2.59–5.75, p = 3:5E-07), the reduction of pos-
itive and negative symptoms was 1.18 (95% CI 0.63–1.73,
p = 2:78E-05) and 0.93 (95% CI 0.39–1.48, p = 7:94E-04),
respectively. This suggested that the antipsychotic treat-
ment during Phase I trial had positive outcomes for the
CATIE patients as a whole. When the classes were ana-
lyzed separately, Class I had the most significant improve-
ments in symptom counts for the total (mean diff=5.47,
95% CI 2.76–8.19, p = 1:02E-04), positive (mean diff=1.26,
95% CI 0.31–2.22, p = 9:90E-03), and negative (mean
diff=1.36, 95% CI 0.47–2.25, p = 2:81E-03) symptoms by
the end of Phase I trial. Class I results remained significant
after Bonferroni correction (3 tests for each category). Class
II had lower total symptoms (mean diff=3.90, 95% CI 0.78–
7.03, mean diff=2.18), and Class IV had lower negative symp-
toms (mean diff 2.18, 95% CI 0.53–3.82, p = 0:0111). In clear
contrast, Classes III and V had no significant changes for the
total, positive, and negative symptoms.
2.4. Subtype Class Association with Neurocognitive Functions.
We examined the changes of neurocognitive functions by
comparing the data from baseline and Visit 6, which was
approximately 170 days into Phase I trial (mean = 173:40, s:
e: = 0:46). We used the data from Visit 6, because it gave us
the largest sample size for neurocognitive function analyses.
As shown in Table 3, Phase I treatment did have a significant
improvement for cognitive functions when all subjects were
analyzed together (VIGILANCE, mean diff=−0.30, 95% CI
−0.40–−0.19, p = 3:0E-07; PROCESSING SPEED, mean
diff=−0.24, 95% CI −0.32–−0.17, p = 6:8E-10; WORKING
MEMORY, mean diff=−0.20, 95% CI −0.29–−0.11, p = 2:8
E-05; and REASONING, mean diff=−0.27, 95% CI −0.38–
−0.17, p = 5:8E-07). When the classes or subtypes were ana-
lyzed separately, Class I showed significant improvements
for all cognitive domains (VIGILANCE, p = 5:8E-07, 95%
CI −0.40–−0.06, p = 0:0099; PROCESSING SPEED, mean
diff = −0:20, 95% CI −0.31–−0.09, p = 0:0006; WORKING
MEMORY, mean diff=−0.21, 95% CI −0.34–−0.08, p =
0:0023; and REASONING, mean diff=−0.28, 95% CI
−0.45–−0.11, p = 0:0015), which all passed Bonferroni cor-
rection (4 tests for each domain). Class II had an improve-
ment in PROCESSING SPEED only, and Class III had
improvement for VIGILANCE only. Class V had improve-
ments for VIGILANCE and PROCESSING SPEED. Class
IV showed a tendency of improvement in all domains but
only REASONING survived multiple testing correction.
2.5. Subtype Class Association with Clinical Laboratory Tests.
The purpose to include these tests was to find whether
there were any laboratory tests associated with our subtype
classification. Using the baseline data to compare to Class
I, we found that patients from Class II had lower levels
of bilirubin effect size =−0.09, p = 0:058) and uric acid
(effect size =−0.46, p = 0:0243) and that patients from
Class V had a higher level of prolactin (effect size = 9:74,
p = 0:0365) (Table S2).
Next, we conducted paired t-tests to compare whether
any of the laboratory tests changed between the baseline
and at the end of the Phase I trial. These statistical tests would
provide us information on how Phase I treatment impacted
the patients and how they related to our subtype classifica-
tion. When all subjects were analyzed together at the end of
the Phase I trial, patients had a higher level of calcium
(mean diff = 0:08, 95% CI 0.04–0.12, p = 0:0003) and phos-
phorus (mean diff = 0:10, 95% CI 0.04–0.17, p = 0:0029), as
compared to their baseline measurement (Table 4). When
each class was analyzed separately, Class I patients had lower
HDL than that measured at baseline (mean diff=−2.25, 95%
CI −3.70–−0.79, p = 0:0027). Both Classes III and V had
higher level of phosphorus (mean diff = 0:19 and 0.17; 95%
CI 0.02–0.37 and 0.02–0.32; p = 0:0282 and 0.0276, respec-
tively). In addition, Class V also had higher levels of HDL
and calcium (mean diff = 2:22 and 0.14; 95% CI 0.30–4.13
and 0.04–0.24; p = 0:0239 and 0.0084, respectively). The
results from Classes III and V suggested the patients from
these two groups might have metabolic syndrome, a possible
Table 1: Traits genetically related to schizophrenia.
Trait
MGS SSCCS CATIE
Estimate Std.Err Z Pr >∣z ∣ð Þ Estimate Std.Err Z Pr >∣z ∣ð Þ Estimate Std.Err Z Pr >∣z ∣ð Þ
BMI −317.20 198.30 −1.60 0.1096 −504.37 166.03 −3.04 0.0024 −876.75 384.79 −2.28 0.0227
Cannabis 30.67 19.17 1.60 0.1097 44.29 16.62 2.67 0.0077 33.10 37.81 0.88 0.3813
evrSmk 271.40 79.98 3.39 0.0007 354.79 69.68 5.09 3.55E-07 285.55 149.62 1.91 0.0563
MEM 1215.00 306.20 3.97 7.21E-05 1198.37 258.63 4.63 3.60E-06 837.03 563.61 1.49 0.1375
NEW_BIP 901.60 50.65 17.80 2.00E-16 582.88 41.94 13.90 2.00E-16 775.78 95.36 8.14 4.10E-16
Openness 36.04 14.06 2.56 0.0104 26.49 11.80 2.25 0.0247 74.71 26.85 2.78 0.0054
OPPH −1215.00 606.10 −2.01 0.0449 −790.07 506.85 −1.56 0.1190 −759.07 1023.04 −0.74 0.4581
SWB −716.70 312.00 −2.30 0.0216 −967.25 262.97 −3.68 0.0002 170.78 590.56 0.29 0.7724
VNR −618.60 159.50 −3.88 0.0001 −455.89 138.07 −3.30 0.0010 −523.70 320.92 −1.63 0.1027
YoS 973.50 426.90 2.28 0.0226 1318.65 361.70 3.65 0.0003 −827.34 819.49 −1.01 0.3127
MGS: Molecular Genetics of Schizophrenia; SSCCS: Swedish Schizophrenia Case-Control Study; CATIE: Clinical Antipsychotic Trials for Intervention
Effectiveness; BMI: body mass index; Cannabis: cannabis dependence; evrSmk: ever smoker vs never smoker; MEM: working memory; NEW_BIP: PGC
Phase II bipolar disorder; Openness: neoopenness; OPPH: one person income per household; SWB: subjective wellbeing; VNR: verbal and numeric
reasoning; YoS: years of school attended.
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side effect from antipsychotics. Furthermore, Class IV had
significant changes for cell counts of decreased lymphocytes
(mean diff=−3.12, 95% CI −5.32–−0.92, p = 0:0065) and
increased neutrophils (mean diff = 3:04, 95% CI 0.47–5.61,
p = 0:0214). Therefore, neutrophil to lymphocyte ratio
(NLR) was increased in this group, suggesting those patients
were under inflammation or linked to immune dysfunctions.
2.6. Post Hoc Analyses of Other Clinical Features and
Laboratory Tests. To explore whether these subtypes had
other specific clinical features documented in the CATIE
dataset, we conducted post hoc analyses with the data of
the structured clinical interview for DSM-IV axis I disorders
(SCID), a clinical global impression (CGI), and trial disconti-
nuation—the major outcome measures for the CATIE study.
From the SCID data, we found that compared to Class I,
Class IV had older age when first prescribed antipsychotic
medicine (effect size = 2:70, p = 0:0363) and was more likely
to have a family history of mental illness (effect size = 0:69,
p = 0:0331) (Table S3). From CGI data, Class II was more
likely to use tobacco products in the last 3 months
(effect size = 0:64, p = 0:0219) (Table S4). From the data of
medication discontinuation, we found that Class IV
patients were less likely to discontinue their clinical trials
even there was no treatment effect (effect size =−0.87, p =
0:0299) (Table S5). While the results from post hoc
analyses were suggestive and could not survive multiple test
correction, they were consistent with the results from the
analyses of clinical symptoms and neurocognitive functions.
3. Conclusion and Discussion
In this study, we used the differentially shared genetic liability
between schizophrenia and comorbid traits to classify and
subtype schizophrenia. Using the PRSs from 10 comorbid
traits, we classified the 435 patients in the CATIE study into
5 classes. As summarized in Table 5, patients from Class I
had the best responses to antipsychotic therapy for symptom
reduction at the end of Phase I trial and improvements for
cognitive functions at Visit 6. This class could be considered
treatment responsive group. After treatment, Class II showed

























































Figure 2: Cluster dendrograms based on 10 traits genetically related to schizophrenia. Cluster dendrograms of the MGS (a), SSCCS (b), and
CATIE (c) datasets. The Roman numbers indicated the classes used in our association analyses. For the MGS and SSCCS datasets, subjects
were classified into 4 classes, and for the CATIE dataset, subjects were classified into 5 classes. The classes were color-coded.
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positive symptoms and improvement for PROCESSING
SPEED. Class IV was uniquely responsive to treatment for
negative symptoms and tended to improve for all cognitive
domains. Interestingly, Class IV had a significant decrease
in cell count for lymphocytes but an increase for neutrophils
at the end of Phase I trial, suggesting that the patients in Class
IV may have an ongoing inflammation condition or immune
dysfunction. In contrast, patients in both Classes III and V
did not have symptom reduction by the end of Phase I trial
but only partial improvements for cognitive function.
Patients in Class III had a higher level of phosphorus by the
end of Phase I. Similarly, patients in Class V also had a higher
level of phosphorus, while they had additional higher levels of
HDL and calcium. Based on their treatment outcomes, Classes
III and V could be considered treatment-resistant. The
changes in laboratory tests from Classes III and V were
indicative of the development of metabolic syndrome-related
to antipsychotic drug treatment. A significant increase in
phosphorus levels has been linked to some schizophrenia
clinical subtypes [54]. The side effects may interfere with the
treatment compliance that causes the treatment-resistant.
Overall, these five classes showed some unique patterns with
regard to clinical symptoms, cognitive functions, treatment
outcomes, laboratory tests, and other clinical features. These
results were consistent with the hypothesis that partially
shared genetic liability between schizophrenia and comorbid
traits could be used to classify patients into subtypes with
distinct underlying biology.
As mentioned in the introduction, although there were
attempts to subtyping schizophrenia using varying approaches,
our study is the first to combine genetic liability to schizophre-
nia and other comorbid conditions for subtype classification.
Our approach differs from previous studies in two aspects.
First, our approach is systematic and data-driven. We used
genome-wide association data to evaluate genetic liability to
schizophrenia. More and more evidence suggests that the
genetic architecture of schizophrenia is complex, and causal





































































Figure 3: Boxplot of baseline clinical symptoms by class. Class II had statistically lower total symptom counts and negative symptoms. The
numbers shown were medians of symptom counts for the classes.
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liability across the entire genome could reveal the difference
between individual patients. Grouping patients based on their
genetic liability, i.e., subtyping, could reduce the heterogeneity
within the group, leading to a better understanding of the
underlying biology and new treatment strategy. The availabil-
ity of genome-wide genetic data makes this data-driven
approach feasible. To our knowledge, no previous study uses
genome-wide data to address this issue. While there is room
for improvement, our exploratory results are promising and
encouraging. Second, our approach integrates partially over-
lapped genetic liability from comorbid conditions to subtype
schizophrenia patients. Previous studies, regardless of the use
of clinical symptoms, neurocognitive functions, or treatment
outcomes, it is schizophrenia-centric, comorbid conditions
rarely contribute to the subtyping. This is partially due to the
difficulty to differentiate the same symptoms obtained from
schizophrenia and comorbid conditions. With the use of
genome-wide genetic profiling, i.e., PRSs, from comorbid
conditions, we could distinguish to what extent that the bipolar
disorder and major depression factors contribute to schizo-
phrenia. When multiple comorbid conditions are incorpo-
rated, the difference between individual patients would be
more distinctive, leading to better separation of subgroups or
subtypes. The finding that different classes have a distinct
association with clinical symptoms and laboratory tests is
supportive of this notion.
Our study has important implications. First, our classifi-
cation is associated with treatment outcomes. Classes I and
IV had better outcomes as measured by symptom count
reduction and improvements in 4 aspects of cognitive
function. Class IV was also less likely to discontinue medica-
tion even though the antipsychotic drugs showed no effects.
In contrast, Classes III and V had no reduction of symptoms
but only partial improvements in cognitive function by the
end of the Phase I trial. This contrast in treatment outcomes
is of clinical importance, especially for prognostic prediction.
Second, our classification is associated with specific labora-
tory tests. Clinical laboratory tests are a cornerstone of
modern medicine; they constitute the basis for the diagnosis
and treatment for many physical diseases. Our analyses of the
CATIE dataset indicated that Class IV was associated with
the cell count changes of lymphocytes and neutrophils
between the baseline and the end of Phase I trial. As we all
know, both lymphocytes and neutrophils are important parts
of the immune system. Lymphocytes are responsible for
antigen recognition and antibody production, while neutro-
phils respond to inflammation and kill invaded microorgan-
isms and damaged cells. Since the connection between
schizophrenia and the immune system is well documented
in the literature, this specific association of Class IV and the
immune cells suggests unique underlying pathophysiology.
On the other hand, an elevated NLR is widely considered as
an indicator of inflammation, because the physiological
response of leukocytes to inflammation often leads to higher
neutrophils and lower lymphocytes in the body [55]. Indeed,
NLR has been reported to be related to the different stages of
schizophrenia, supporting inflammation or immune hypoth-
esis in schizophrenia [56]. For Classes III and V, the elevated
phosphorus accompanying with other laboratory test
changes such as HDL and electrolytes indicate that those
Table 2: Symptom count changes between the baseline and the end of Phase I trial.
All subjects Class I Class II Class III Class IV Class V
Total symptom
Mean Diff 4.17 5.47 3.90 1.12 4.89 3.41
95% CI 2.59-5.75 2.76-8.19 0.78-7.03 −3.34-5.58 −0.12-9.90 −0.32-7.14
t 5.17 3.98 2.48 3.18 1.97 1.82
df 435 171 81 56 44 79
P 3.50E-07 1.02E-04 0.0151 0.6160 0.0557 0.0725
Positive symptom
Mean Diff 1.18 1.26 1.02 0.82 1.60 1.20
95% CI 0.63-1.73 0.31-2.22 0.00-2.05 −0.69-2.34 −0.22-3.42 −0.10-2.50
t 4.24 2.61 2.00 1.09 1.77 1.83
df 435 171 81 56 44 79
P 2.78E-05 9.90E-03 0.0492 0.2801 0.0839 0.0707
Negative symptom
Mean Diff 0.93 1.36 0.65 −0.63 2.18 0.73
95% CI 0.39-1.48 0.47-2.25 −0.54-1.83 −2.32-1.05 0.53-3.82 −0.49-1.94
t 3.38 3.03 1.08 −0.75 2.65 1.19
df 435 171 81 56 44 79
P 7.94E-04 2.81E-03 0.2817 0.4556 0.0111 0.2382
Mean Diff: mean difference between the baseline and at the end of Phase I trial; 95% CI: 95% confidence interval; t: test t value; df: degree of freedom; P values
≤0.05 were highlighted by bold.
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patients may have ongoing metabolic syndrome. The specific
association between these laboratory tests and subtype
classes implies distinctive underlying biology. These tests
may be used as biomarkers for subtyping and treatment
evaluation. Third, the features associated with the subtype
classes provide new insights for our understanding of disease
pathophysiology and new strategies for treatment. For
example, Class IV had a significant reduction of negative
symptoms, but not a reduction of positive symptoms after
Phase I trial. An elevated NLR from a simple complete blood
count (CBC) often reveals an ongoing inflammation. This
would explain why positive symptoms did not have a reduc-
tion among those patients, for whom treatment including
adjunctive use of nonsteroid anti-inflammatory drugs would
be beneficial, as previously reported [57]. Class IV was also
associated with older age when the patients were first
prescribed antipsychotic medicine and a family history of
mental illness. This subtype also had an improvement for
reasoning after Phase I. When all this information is consid-
ered together, some intriguing questions emerge. Is there a
relationship between positive symptoms and inflammation
or immune dysfunction? Would a treatment strategy that
combines antipsychotics and anti-inflammatory drugs or
immune therapy perform better for Class IV patients than a
standard antipsychotics treatment? Do the age of onset
(inferred by the age of the first prescription of antipsychotics)
and family history of mental illness relate to treatment out-
comes and reasoning? For Class V, due to its link to the
Table 3: Change of cognitive functions between baseline and Visit
6.
Mean Diff t-value df 95% CI p value
VIGILANCE
All subjects −0.30 −5.31 200 −0.40–−0.19 3.0E-07
Class I −0.23 −2.64 79 −0.40–−0.06 0.0099
Class II −0.24 −1.45 33 −0.59–0.10 0.1578
Class III −0.41 −2.97 24 −0.70–−0.13 0.0066
Class IV −0.34 −2.41 23 −0.63–−0.05 0.0242
Class V −0.38 −3.03 37 −0.63–−0.13 0.0045
PROCESSING SPEED
All subjects −0.24 −6.45 224 −0.32–−0.17 6.8E-10
Class I −0.20 −3.56 87 −0.31–−0.09 0.0006
Class II −0.29 −2.85 38 −0.50–−0.08 0.0071
Class III −0.29 −2.41 27 −0.54–−0.04 0.0229
Class IV −0.26 −2.17 26 −0.51–−0.01 0.0395
Class V −0.25 −3.23 42 −0.40–−0.09 0.0024
WORKING MEMORY
All subjects −0.20 −4.27 224 −0.29–−0.11 2.8E-05
Class I −0.21 −3.14 87 −0.34–−0.08 0.0023
Class II −0.18 −1.36 38 −0.44–0.09 0.1819
Class III −0.09 −0.57 27 −0.44–0.25 0.5740
Class IV −0.26 −2.12 26 −0.52–−0.01 0.0433
Class V −0.21 −2.32 42 −0.39–−0.03 0.0252
REASONING
All subjects −0.27 −5.15 224 −0.38–−0.17 5.8E-07
Class I −0.28 −3.27 87 −0.45–−0.11 0.0015
Class II −0.24 −1.95 38 −0.50–0.01 0.0585
Class III −0.27 −1.67 27 −0.60–0.06 0.1056
Class IV −0.40 −2.78 26 −0.69–−0.10 0.0100
Class V −0.20 −1.66 42 −0.44–0.04 0.1053
Mean Diff: mean difference between the baseline and Visit 6; 95% CI: 95%
confident interval; t-value: Test t value; df: Degree of freedom; P values
≤0.05 were highlighted in bold.
Table 4: Changes of laboratory tests between baseline and end of
Phase I trial.
Mean Diff t-value df 95% CI p value
HDL
All subjects −0.07 −0.15 419 −0.99–0.85 0.8833
Class I −2.25 −3.04 168 −3.70–−0.79 0.0027
Class II −0.68 −0.61 78 −2.90–1.53 0.5406
Class III 2.94 1.98 49 −0.05–5.93 0.0537
Class IV 1.93 1.55 43 −0.57–4.44 0.1274
Class V 2.22 2.30 77 0.30–4.13 0.0239
Calcium
All subjects 0.08 3.61 419 0.04–0.12 0.0003
Class I 0.05 1.28 168 −0.02–0.13 0.2041
Class II 0.08 1.80 77 −0.01–0.18 0.0763
Class III 0.07 1.10 50 −0.06–0.21 0.2757
Class IV 0.12 1.79 43 −0.02–0.26 0.0806
Class V 0.14 2.71 77 0.04–0.24 0.0084
Phosphorus
All subjects 0.10 2.99 419 0.04–0.17 0.0029
Class I 0.02 0.41 168 −0.09–0.14 0.6858
Class II 0.12 1.49 77 −0.04–0.28 0.1409
Class III 0.19 2.26 50 0.02–0.37 0.0282
Class IV 0.16 1.54 43 −0.05–0.38 0.1318
Class V 0.17 2.25 77 0.02–0.32 0.0276
Lymphocytes
All subjects 0.23 0.55 416 −0.58–1.04 0.5806
Class I 0.67 1.06 164 −0.58–1.90 0.2915
Class II 0.68 0.68 78 −1.11–2.47 0.4531
Class III −0.14 −0.12 52 −2.53–2.25 0.9084
Class IV −3.12 −2.86 43 −5.32–−0.92 0.0065
Class V 1.00 0.90 75 −1.21–3.21 0.3684
Neutrophils
All subjects −0.48 −1.02 416 −1.40–0.44 0.3092
Class I −0.96 −1.42 164 −2.30–0.38 0.1588
Class II −0.98 −0.91 78 −3.12–1.16 0.3660
Class III 0.34 0.23 52 −2.58–3.26 0.8161
Class IV 3.04 2.39 43 0.47–5.61 0.0214
Class V −1.51 −1.22 75 −3.97–0.96 0.2265
Mean Diff: mean difference between the baseline and Phase I; 95% CI: 95%
confidence interval; t-value: test t value; df: degree of freedom; P values
≤0.05 were highlighted by bold; HDL: high-density lipoproteins.
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metabolic syndrome, would simultaneous treatments with
antipsychotics and drugs for the metabolic syndrome, or
avoidance of antipsychotic drugs that increase the risk for
developing metabolic syndrome, lead to better outcomes? Is
an elevated level of phosphorus more related to treatment-
resistant? Further investigation of these questions could help
our understanding of subtype-specific mechanisms and
provide the basis for the development of subtype-specific
treatments.
Our study has some limitations. First, although we found
class-specific associations with symptom counts, treatment
outcomes, cognitive improvements, and clinical laboratory
tests in CATIE patients, we could not validate these findings
with independent samples. This is largely due to the limita-
tion of available data. Further study with appropriate data
is necessary to confirm our results. Second, although we
screened 25 comorbid traits, our screening was by no means
exhaustive. When more traits are screened, more candidate
traits could be included and different cluster structures may
be found. It may require multiple iterations and additional
comorbid traits to reach an optimal cluster structure. Third,
the demographics and the clinical data from the MGS and
SSCCS datasets are currently not publicly available. Based
on the diagnosis only, we may have missed some hidden
confounder factors when we compare the CATIE sample
with those two samples.
In summary, this study provides the first demonstration
that differentially shared genetic variants between comorbid
traits can be utilized to subtype schizophrenia into classes
associated with specific clinical features, treatment outcomes,
cognitive improvements, and laboratory tests. Patients in the
CATIE study were classified into 5 classes. Classes I and IV
had varying levels of treatment responses as measured by
symptom reduction and had cognitive improvements for all
measured domains, with Class I having better outcomes.
They would be the treatment responsive group. Classes III
and V had no symptom reductions but with only partial
cognitive improvement after Phase I trial. They could be
considered the treatment-resistant group. Using laboratory
tests as a measure, Class IV would have ongoing inflamma-
tion or immune dysfunction, and Classes III and V may have
metabolic syndrome. This classification may be translated
into a class-specific treatment strategy. Our study is of clini-
cal importance and mechanistic significance; it provides the
evidence that data-driven subtyping, biology-based, and
subtype-specific treatment of schizophrenia may be accom-
plishable. However, due to the limitation of data availability
mentioned above, our findings need further validation.
4. Methods
4.1. Genotype Datasets.We applied for and obtained the geno-
type and clinical data for the MGS [43], SSCCS [7], and the
CATIE [52, 53] datasets from NIMH Genetics Repository
(https://www.nimhgenetics.org/). Both the MGS and SSCCS
datasets were large genetic studies of schizophrenia using a
case-control design. The CATIE study was a clinical trial to
evaluate the efficacy of antipsychotics treatment on schizophre-
nia. The MGS and CATIE datasets were genotyped with Affy-
metrix 6.0 microarray with about 906,600 SNPs. The SSCCS
was typed with Illumina OmniExpression array with 713,599
SNPs. In order to have the same markers across the MGS,
SSCCS, and CATIE datasets, we used the IMPUTE2 [58] to
impute the downloaded genotypes with the 1000 Genome hap-
lotypes as reference.Markers with the INFO value<0.4 were fil-
tered out. Details of imputation were described previously [59].
The genetic scores were used for the evaluation of the
genetic relationships between schizophrenia and comorbid
traits. Imputed genotype data were used for PRS calcula-
tion from MGS, SSCCS, and CATIE datasets including
subjects (cases and controls). All subjects used were of
European ancestry.
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For cluster analyses or subtyping, only cases (affected
schizophrenia individuals) were used as we are only inter-
ested in the subtype for the patients. The MGS dataset had
2,681 cases, SSCCS had 2,895 cases, and CATIE had 435
cases. Overall, MGS and SSCCS were used to discover traits
comorbid with schizophrenia and explore cluster structure.
The CATIE was used to verify the cluster structure and vali-
date subtypes with clinical symptoms, treatment outcomes,
neurocognitive functions, and laboratory tests (Figure 1).
4.2. Comorbid Trait Selection and Genetic Relationship with
Schizophrenia. Based on the literature search by keywords
“schizophrenia”, “comorbidity”, and “genome-wide associa-
tion studies”, or “GWAS” from https://pubmed.ncbi.nlm
.nih.gov/, we selected 25 psychiatric and physical diseases/-
traits that are comorbid with schizophrenia. We then down-
loaded the GWAS summary statistics from the GWAS
catalog website (various sources). A total of 25 traits chosen
were chosen (Table S1). We calculated PRSs for each
specific trait [60] using markers with p values ≤0.05 in both
schizophrenia and the candidate traits, which had been
shown to optimally capture phenotypic variance in a
previous study [8]. Scores were weighted by the logarithm
of the odds ratio (OR) for dichromate traits or beta for
quantitative traits according to PLINK [61].
Next, we evaluated the genetic relationships between
these traits and schizophrenia using logistic regression. Only
those traits with regression p values ≤0.15 in both the MGS
and SSCCS and had the same direction of effect were
included as potential classifiers for cluster analyses.
4.3. Cluster Analyses.We used the R platform to conduct our
analyses. PRSs for schizophrenia [8] and the 10 selected traits
were used in cluster analyses. The 10 selected traits were PGC
Phase II bipolar disorder (BIP) [44]; body mass index (BMI)
[62]; cannabis dependence (cannabis) [45]; ever smokers vs
never smoker (evrSmk) [46]; working memory (MEM)
[48]; verbal and numeric reasoning (VNR) [48]; neoopenness
(OPEN) [49]; one person income per household (OPPH)
[63]; subjective wellbeing (SWB) [47]; and years of schooling
(YoS) [50]. We used the “NbClust” package [51] to explore
the appropriate solution for the number of clusters based
on Euclidean distances. The majority rule was used to select
the number of clusters. In these analyses, the MGS dataset
was used to explore likely cluster structure with different
clustering parameters. Once a reasonable structure was
found, the SSCCS dataset was used to validate the cluster
structure using the same parameters. When a stable and
consistent cluster structure was identified, the same parame-
ters would be applied to the CATIE dataset to cluster the
patients. The clusters from the CATIE dataset were used for
membership association analyses with clinical, neurological,
and laboratory data.
4.4. Clinical and Neurocognitive Data. The CATIE study was
a double-blind randomized clinical trial to evaluate the effec-
tiveness of antipsychotic drugs. There were 5 drugs used in
the Phase I trial: perphenazine, olanzapine, quetiapine,
risperidone, and ziprasidone. Participants were assigned a
drug randomly and evaluated with extensive assessments
for clinical symptoms, neurocognitive functions, and labora-
tory tests at the enrollment (baseline) and regular follow-ups
for 18 months. We used the data obtained at the baseline,
Visit 6 (about 6 months into Phase I), and at the end of the
Phase I trial. Clinical symptoms were evaluated with the
positive and negative syndrome scale (PANSS) [64].
Symptom count data were treated as quantitative measures
without any transformation. We used the difference of symp-
tom counts between the baseline and that at the end of Phase
I trial to define treatment outcomes. If the difference was
statistically significant, then the treatment outcome was
judged to be effective. We used a paired t-test to compare
the means for each symptom category separately. Data from
a structured clinical interview for DSM IV (SCID), a clinical
global impression (CGI), and treatment discontinuation
were used in post hoc analyses. We used the neurocognitive
data from the baseline and at Visit 6 to determine the
improvement of neurocognitive functions. Neurocognitive
functions, as defined in the CATIE study, included vigilance
(VIGILANCE), processing speed (PROCESSING SPEED),
reasoning (REASON), and working memory (WORKING
MEMORY). We took the data as provided by NIMH Genetic
Repository. More details of the CATIE neurocognitive tests
were described elsewhere [65, 66].
4.5. Clinical Laboratory Test Data. The CATIE study had
data for some standard laboratory tests at the enrollment
and follow-up checks. We selected the data for bilirubin, uric
acid, prolactin, and cell counts for neutrophils, eosinophils,
lymphocytes, and monocytes for this study. The motivation
for the inclusion of laboratory tests was to evaluate whether
any of these tests had the potential for use as biomarkers
for the classes resulting from our cluster analysis. The tests
selected were related to oxidative stress, inflammation,
hyperprolactinemia, and immune functions. In the literature,
there were suggestions that oxidative stress could be an
underlying factor for schizophrenia [67], and antipsychotic
medicine led to increased levels of prolactin [68]. Dysregula-
tion of the immune system and inflammation in patients of
schizophrenia is well documented [69–71]. Both data at the
baseline and at the end of Phase I were used.
4.6. Statistical Analyses. Once we grouped the patients into
classes, we conducted analyses to evaluate whether these
classes were associated with clinical features, treatment
outcomes, neurocognitive functions, and laboratory tests by
linear and logistic regression. Baseline assessments of clinical
symptoms, neurocognitive and laboratory tests were used in
these analyses where functional data were treated as quanti-
tative outcomes and class memberships were treated as facto-
rial predictors with Class I as a reference, sex, age, and
assigned antipsychotics as covariates. The outcomes of Phase
I treatment were evaluated by paired t-tests to compare the
means of tested items between the baseline, Visit 6, and that
at the end of Phase I trial. In all tests, p values were reported
without multiple test correction.
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